Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Announces Third Quarter 2018 Results and Update
November 07, 2018 16:01 ET
|
Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
October 31, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Announces Second Quarter 2018 Results and Update
August 06, 2018 16:05 ET
|
Editas Medicine, Inc.
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...
Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
July 30, 2018 16:02 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
Editas Medicine to Participate in The JMP Securities Life Sciences Conference
June 13, 2018 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor...
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
May 08, 2018 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of...
Editas Medicine Announces First Quarter 2018 Results and Update
May 03, 2018 16:01 ET
|
Editas Medicine, Inc.
Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield, Ph.D. Cash, cash equivalents, and...
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
April 26, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
March 06, 2018 16:01 ET
|
Editas Medicine, Inc.
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22...